GIM
MRNA icon

Glenmede Investment Management’s Moderna MRNA Stock Holding History

Glenmede Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$281K Buy
10,869
+350
+3% +$9.76K ﹤0.01% 1139
2025
Q2 		$290K Buy
+10,519
New +$277K ﹤0.01% 1115

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Glenmede Investment Management's MRNA Position: Q3 2025 in Review

Glenmede Investment Management increased its Moderna (MRNA) stake by 3.3% in Q3 2025, buying an estimated $9.76K and bringing the position to 10,869 shares worth $281K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Glenmede Investment Management first reported a position in MRNA in Q2 2025 and has held it in 2 quarters since. The position peaked at $290K in Q2 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Glenmede Investment Management held 10,869 shares of Moderna worth $281K as of Q3 2025.
  • Glenmede Investment Management bought 350 Moderna shares in Q3 2025, an estimated $9.76K.
  • Moderna made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1139 holding.
  • Glenmede Investment Management first reported a position in Moderna in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Moderna position peaked at $290K in Q2 2025.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.